FDA Plans Major Operational Reforms and Clinical Trial Modernization

The FDA has announced plans for a significant overhaul of its inspectional operations as part of its "Simple Reform" initiative. Concurrently, the acting director of CBER proposed modernizing the investigational new drug (IND) process to enhance the U.S.'s appeal for early-phase clinical trials. These reforms aim to improve agency efficiency and address concerns about the nation's competitiveness in pharmaceutical research.